Dinesh V. Patel, Ph.D
President and CEO at Protagonist Therapeutics. Based in Newark, California.
- Rank
- 2116th of 14,452
- Companies held
- 1
- Largest holding
- PTGX, 100.0% of total
- Latest SEC filing
- Sep 10, 2026
What the $64.9M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| Protagonist Therapeutics PTGX Common Stock | Directly | 522,968 | $124.02 | $64.9M | 100.0% | Form 4, Sep 10, 2026 |
Share counts are the amounts Dinesh V. Patel, Ph.D reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Sold | PTGX | 7,278 | $144.10 | $1.0M | View |
| Sep 9, 2026 | Sold | PTGX | 63,548 | $146.18 | $9.3M | View |
| Sep 8, 2026 | Sold | PTGX | 54,174 | $145.87 | $7.9M | View |
| Aug 11, 2026 | Sold | PTGX | 34,239 | $148.52 | $5.1M | View |
| Aug 10, 2026 | Sold | PTGX | 65,761 | $149.11 | $9.8M | View |
| May 12, 2026 | Sold | PTGX | 75,000 | $100.12 | $7.5M | View |
| May 12, 2026 | Sold | PTGX | 75,000 | $100.12 | $7.5M | View |
| Mar 25, 2026 | Sold | PTGX | 54,641 | $101.00 | $5.5M | View |
| Mar 24, 2026 | Sold | PTGX | 59 | $101.00 | $6K | View |
| Jan 27, 2026 | Sold | PTGX | 4,068 | $83.19 | $338K | View |
| Jan 26, 2026 | Sold | PTGX | 10,685 | $84.00 | $898K | View |
| Jan 26, 2026 | Sold | PTGX | 14,205 | $84.05 | $1.2M | View |
| Jan 23, 2026 | Sold | PTGX | 19,315 | $84.59 | $1.6M | View |
| Jan 20, 2026 | Sold | PTGX | 34,438 | $82.48 | $2.8M | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 2113 | Charles William Digges Jr. Director, Central Bancompany. Jefferson City, MO | $64.9M |
| 2114 | Thomas W. Florsheim CHAIRMAN & CEO, Weyco Group. Glendale, WI | $64.9M |
| 2115 | P. Kent Hawryluk President & CEO, MBX Biosciences. Carmel, IN | $64.9M |
| 2116 | Dinesh V. Patel, Ph.D President and CEO, Protagonist Therapeutics. Newark, CA | $64.9M |
| 2117 | Sean Michael Walters Chief Revenue Officer, Datadog. New York, NY | $64.9M |
| 2118 | Mark Brazeal Chief Legal & Corp Affairs Ofc, Broadcom. Palo Alto, CA | $64.8M |
| 2119 | Paul Badawi President and CEO, Sight Sciences. Menlo Park, CA | $64.7M |
Other Protagonist Therapeutics insiders
All PTGX insiders- Suneel Gupta$33.2MChief Development Officer. #3474 overall
- David Y. Liu$20.8MChief R&D Strategy Officer. #5042 overall
- Arturo Molina, MD$10.1MChief Medical Officer. #8699 overall
- Harold E. Selick$7.5MDirector. #10796 overall
- Asif Ali$7.3MChief Financial Officer. #11055 overall
Questions
How much stock does Dinesh V. Patel, Ph.D own?
Dinesh V. Patel, Ph.D holds $64,858,491 in listed stock based on SEC filings and current prices, mostly Protagonist Therapeutics (PTGX). That ranks 2116th on the Stock Rich List.
Is this Dinesh V. Patel, Ph.D's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Dinesh V. Patel, Ph.D last buy or sell stock?
The most recent open-market trade on file is a sale of 7,278 PTGX shares on Sep 10, 2026 at $144.10.